Observational Cohort Study Evaluating the Use and Efficacy of Pomalidomide in Patients With Multiple Myeloma in Routine Clinical Practice
Latest Information Update: 29 Jun 2022
Price :
$35 *
At a glance
- Drugs Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms MIROIR
- Sponsors Celgene Corporation
- 23 Jun 2022 Status changed from active, no longer recruiting to completed.
- 20 Jul 2020 Planned primary completion date changed from 30 Sep 2019 to 30 Sep 2020.
- 20 Jul 2020 Status changed from recruiting to active, no longer recruiting.